In our case series, the IBD patients were from five tertiary IBD referral centers, which meant they were more likely to exhibit more severe IBD symptoms, thus requiring anti-TNF therapy more frequently than patients in a primary care medical setting. This evidence concerns the gene TNF and inflammatory bowel disease.